Sign in: Staff/Students
Today sees the launch of the new UK Coronavirus Immunology Consortium (UK-CIC), which aims to address key unanswered questions about immunity and COVID-19 to help develop better diagnostics, treatments and vaccines.
The Liverpool Outbreak Laboratories will support this major collaboration of 17 UK institutions, who are combining their research expertise to fight the coronavirus pandemic.
The consortium has received £6.5million of funding over 12 months from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), the largest immunology grant awarded to tackle the COVID-19 pandemic.
The consortium will investigate key questions including:
The project, will use samples and data from major UK COVID-19 projects already underway including ISARIC-4C (characterizing and following more than 75,000 hospitalized patients with COVID-19) and the genomic studies COG-UK (sequencing the SARS-CoV-2 virus genomes) and GenOMICC (sequencing the genomes of people with COVID-19).
UK-CIC is supported by the British Society for Immunology and the Liverpool work is being led by Professor Calum Semple alongside Dr Lance Turtle.
Dr Lance Turtle, Senior Clinical Lecturer in Infectious Diseases at the University of Liverpool, said: “In Liverpool we have expertise in T-cell responses to emerging viruses and we are leading the clinical recruitment nationally of a subset of patients who were hospitalised with severe COVID-19 during the first wave in the UK.
“In collaboration with other UK-CIC members, we will track the immune responses of these patients over time. We will also survey patients for repeat infections, looking to answer the question of whether people who have had severe disease can get the infection again and how their immune response may protect them against this.”
The consortium is led nationally by Professor Paul Moss at the University of Birmingham, who added: “Understanding the complexities of the immune response to SARS-CoV-2 is key to successfully developing new diagnostics, treatments and vaccines against COVID-19. The UK Coronavirus Immunology Consortium will see the UK immunology community come together in an unprecedented way to answer questions that are crucial in helping us control this pandemic, such as how effective immunity is developed and why individuals respond differently to the disease.”
Chief Medical Officer for England and Head of the NIHR Professor Chris Whitty said: “Understanding how our immune systems respond to COVID-19 is key to solving some of the important questions about this new disease, including whether those who have had the disease develop immunity and how long this lasts, and why some are more severely affected. This investment by the NIHR and UKRI will help immunology experts to discover how our immune systems respond to SARS-CoV-2, including our T cell response. This is vital information to help prevent and treat the disease.”
For more information please visit www.uk-cic.org
All recent news
14: Dame Louise Ellman and Professor William Hope
Play your part in #TeamLivUni
How we are safely welcoming live audiences back for Liverpool Literary Festival 2021
Our favourite images from Welcome Week 2021
Heseltine Institute report for LCR APPG leads calls for Westminster to deliver “clean, green and inclusive growth”
Liverpool is leading a new global network to bring together animal & human #coronavirus research communities.
Funded by @UKRI partners include @APHAgovuk @roslininstitute @Pirbright_Inst @Cambridge_Uni
#OneHealth #LivUniCovid @ThePandemicInst @livuniHLS https://bit.ly/3AEEqHr
Preventing the next global pandemics depends on the collective capacity of universities. For @Wonkhe this morning I’ve written about Liverpool, Covid-19 and @ThePandemicInst, and what next: https://wonkhe.com/blogs/if-pandemics-are-predictable-could-they-be-preventable/
Researchers from @livuniHLS have contributed to new research showing that llama antibodies have 'significant potential' as a #COVID19 treatment.
Published in @NatureComms today, the study was led by @RosFrankInst.
#LivUniCovid | @molvirol | @LivUni_IVES